Aurinia Pharmaceuticals (AUPH) Net Cash Flow (2020 - 2026)

Aurinia Pharmaceuticals' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$39.2 million for Q1 2026.

• Quarterly Net Cash Flow fell 130.55% year-over-year to -$39.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.4 million (down 1391.01% YoY) and the FY2025 annual result came in at -$3.2 million, down 109.32% from the prior year.
• Net Cash Flow was -$39.2 million for Q1 2026 at Aurinia Pharmaceuticals, down from $7.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $46.3 million in Q4 2024 and bottomed at -$99.4 million in Q1 2022.
• A 5-year average of -$11.2 million and a median of -$5.2 million in 2023 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 1768.08% in 2024, while the deepest fall reached 325.72% in 2024.
• Aurinia Pharmaceuticals' Net Cash Flow stood at $8.1 million in 2022, then sank by 69.48% to $2.5 million in 2023, then jumped by 1768.08% to $46.3 million in 2024, then tumbled by 84.83% to $7.0 million in 2025, then sank by 658.16% to -$39.2 million in 2026.
• Business Quant data shows AUPH's Net Cash Flow at -$39.2 million in Q1 2026, $7.0 million in Q4 2025, and $20.2 million in Q3 2025.